News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SK Bio-Pharmaceuticals Enters into a Licensing Agreement with Premier Chinese Biopharmaceutical Company



10/20/2011 10:45:50 AM

SEOUL, Korea--(BUSINESS WIRE)--South Korean biotech SK biopharmaceuticals announced yesterday that they entered into a research and development agreement with Medicilon, of Shanghai, China, for their novel new small molecule SKL-PSY that is being developed for the treatment of depression and bipolar disorder.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES